We have observed
15 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after August 01, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
NEW TREATMENTS OF HEPATITIS C VIRUS INFECTION
METHOD FOR TREATING METABOLIC DISORDERS
ALISPORIVR FOR TREATMENT OF HEPATIS C VIRUS INFECTION
METHODS OF TREATING PSORIATIC ARTHRITIS (PSA) USING IL-17 ANTAGONISTS AND PSA RESPONSE OR NON- RESPONSE ALLELES
PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES
ACUTE KIDNEY INJURY
IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION
METHODS OF TREATING GENERALIZED PUSTULAR PSORIASIS (GPP) USING IL-17 ANTAGONISTS
METHODS OF TREATING ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS USING ANTI-IL-17 ANTIBODIES
METHODS OF IMPROVING OR ACCELERATING PHYSICAL RECOVERY AFTER SURGERY FOR HIP FRACTURE
IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS
USE OF IL-17 ANTAGONISTS TO INHIBIT THE PROGRESSION OF STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIS PATIENTS
MYOSTATIN OR ACTIVIN ANTAGONISTS FOR THE TREATMENT OF SARCOPENIA
THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING ANTIBODIES AND METHODS OF USING THE ANTIBODIES